Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 18/20 | 0.41 |
| ▸ | MAP2K2 | P36507 | 16/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6398237 | 0.85 | MAP2K2 (0.46) | KCNH2SCN5AMAP2K1MAP2K2 | |
| SCHEMBL6406131 | 0.81 | MAP2K1 (0.47) | KCNH2MAP2K1MAP2K2BRAF | |
| SCHEMBL6401156 | 0.80 | MAP2K1 (0.42) | KCNH2MAP2K1MAP2K2BRAFMAPK1 | |
| SCHEMBL6187710 | 0.79 | MAP2K1 (0.41) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL6404616 | 0.78 | BCHE (0.37) | MAP2K1MAP2K2 | |
| SCHEMBL6207836 | 0.78 | CHRNA7 (0.46) | KCNH2MAP2K1MAP2K2PIK3CDPIK3R1 | |
| SCHEMBL6208038 | 0.78 | PIM1 (0.45) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL6401090 | 0.77 | MAP2K1 (0.48) | KCNH2MAP2K1MAP2K2BRAF | |
| SCHEMBL6206922 | 0.77 | BCHE (0.37) | KCNH2SCN5AMAP2K1MAP2K2 | |
| SCHEMBL6403726 | 0.77 | PIM1 (0.42) | MAP2K1MAP2K2PIM1CAMK2BBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578736-A1 | MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL-PHENYLAMINE DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-09-28 | — | — | EP | claimed |
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | claimed |
| WO-2004056789-A1 | MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL PHENYLAMINE DERIVATES | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-08 | — | — | WO | claimed |
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004186-A1 | MEK inhibiting compounds | MAPK1, MAP3K1, MAPK3 | KCNH2 3852/4885SCN5A 4475/4885MAP2K1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.